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Recent reports have shown that antibiotics such as macrolide, aminoglycoside, and tetracyclines have
immunomodulatory effects in addition to essential antibiotic effects. These agents may have important
effects on the regulation of cytokine and chemokine production. However, the precise mechanism is un-
known. This time, we used Multi Plex to measure the production of cytokines and chemokines following
tetracycline treatment of lipopolysaccharide (LPS)-induced THP-1 cells. The signaling pathways were in-
vestigated with Western blotting analysis. Three tetracyclines signiﬁcantly suppressed the expression of
cytokines and chemokines induced by LPS. Minocycline (50 μg/ml), tigecycline (50 μg/ml), or doxycycline
(50 μg/ml) were added after treatment with LPS (10 μg/ml). Tumor necrosis factor-α was downregulated
to 16%, 14%, and 8%, respectively, after 60 min compared to treatment with LPS without agents. Interleukin-
8 was downregulated to 43%, 32%, and 26% at 60 min. Macrophage inﬂammatory protein (MIP)-1α was
downregulated to 23%, 33%, and 16% at 120 min. MIP-1β was downregulated to 21%, 11%, and 2% at
120 min. Concerning about signaling pathways, the mechanisms of the three tetracyclines might not be the
same. Although the three tetracyclines showed some differences in the time course, tetracyclines modu-
lated phosphorylation of the NF-κB pathway, p38 and ERK1/2/MAPK pathways, resulting in inhibition of
cytokine and chemokine production. In addition, SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor)
signiﬁcantly suppressed the expression of TNF-α and IL-8 in LPS-stimulated THP-1 cells. And further, the
NF-κB inhibitor, BAY11-7082, almost completely suppressed LPS-induced these two cytokines production.
Thus, more than one signaling pathway may be involved in tetracyclines downregulation of the expression
of LPS-induced cytokines and chemokines in THP-1 cells. And among the three signaling pathways, NF-κB
pathway might be the dominant pathway on tetracyclines modiﬁcation the LPS-induced cytokines pro-
duction in THP-1 cells. In general, minocycline and doxycycline suppressed the production of cytokines and
chemokines in LPS-stimulated THP-1 cell lines via mainly the inhibition of phosphorylation of NF-κB
pathways. Tigecycline has the same structure as the other tetracyclines, however, it showed the different
properties of cytokine modulation in the experimental time course.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tetracycline was discovered in the 1940s and has revealed ef-
fectiveness against various microorganisms including gram-positive
and gram-negative bacteria, chlamydiae, mycoplasmas, rickettsiaeB.V. This is an open access article u
lear factor-kappa B; IκBα/β,
pa B kinase alpha; IKKβ,and protozoan parasites for more than 60 years. Tetracycline has
been used extensively for prophylaxis and therapy in both human
and animal infections. However, recent studies have shown that
tetracycline and its analogs such as minocycline, doxycycline, and
tigecycline, have several non-antibiotic, anti-inﬂammatory proper-
ties including a modulatory effect on immunostimulatory activities
in vitro [1–3].
Doxycycline has a broad-spectrum antibacterial activity and it is
useful for both gram-negative and gram-positive microorganisms. It
inhibits bacterial protein synthesis by binding to the 30S ribosomalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cytokines and chemokines induced by staphylococcal exotoxins in
human peripheral blood mononuclear cells [1]. It also inhibits the
production of interleukin (IL)-1β in lipopolysaccharide (LPS)-stimu-
lated corneal epithelial cells [4]. Thus, doxycycline modulates cyto-
kine production in different types of cell lines. Castro et al. [5] showed
that doxycycline and tetracycline modulate IL-6, IL-1β, tumor necrosis
factor (TNF)-α in patient with dengue hemorrhagic fever. Doxycycline
gives more signiﬁcant effect on modulating cytokine than tetra-
cycline. Both doxycycline and minocycline decreased the production
of TNF-α, IL-6, and IL-8 in a dose-dependent manner [6].
Minocycline has also recently been reported to have additional
effects besides antimicrobial functions. However, the precise me-
chanisms still remain unclear. Tai et al. investigated the effects of
minocycline on cytokine and chemokine production and the ex-
pression levels of intracellular phosphorylated proteins in an in
vitro model of LPS-induced cytokine response [7]. Many recent
studies have elucidated on non-antibiotic properties of minocycline,
including anti-inﬂammatory and anti-apoptotic activities as well as
inhibition of proteolysis, angiogenesis, and tumor metastasis [8].
Tigecycline is the ﬁrst glycylcycline antibiotic to be approved by
the US Food and Drug Administration. Tigecycline derived from
minocycline has an activity against many gram-positive and gram-
negative organisms including methicillin-resistant Staphylococcus
aureus, vancomycin-intermediate and vancomycin-resistant en-
terococci, and extended-spectrum β-lactamase–producing Escher-
ichia coli and Klebsiella pneumoniae [9]. The efﬁcacy of tigecycline
was already reported by Pachon-Ibanez et al. [10]. Pichardo et al.
[11] reported the in vitro activities of tigecycline and imipenem
against 49 isolates of Acinetobacter baumannii, including those
resistant to imipenem. These results showed that tigecycline has
efﬁcient activity against A. baumannii, including strains resistant to
imipenem. Tigecycline is also active against Acinetobacter spp. and
S. maltophilia strains. This agent may play a crucial role in severe
respiratory infections of both nosocomial and community origin
[12]. In addition, tigecycline signiﬁcantly attenuates the expression
and release of nuclear factor-kappa B (NF-κB), TNF-α, and IL-1β, as
well as nitric oxide levels in LPS-induced pheochromocytoma
(PC12) cells. Tigecycline modiﬁes cytokine and chemokine pro-
duction in LPS-induced PC12 cells [13].
The effectiveness of tetracycline and its derivatives in clinical
use in various diseases have been investigated. The other proper-
ties of tetracyclines and their possibility for clinical use have been
shown in rosacea, bullous dermatoses, neutrophilic diseases,
pyoderma gangrenosum, sarcoidosis, cancer metastasis, period-
ontitis and autoimmune disorders [14]. Tetracyclines have also
modulate cytokine production and cytotoxicity [15]. We hy-
pothesized that tetracyclines might inhibit the production of cy-
tokines and chemokines in addition to their conventional anti-
microbial effects and may thus control inﬂammation. The precise
mechanism of modulation of the expression of cytokines and
chemokines by tetracyclines remains unknown. In this study, we
showed that three tetracycline derivatives, minocycline, tigecy-
cline, and doxycycline, have different modulatory effects on ex-
tracellular signal-regulated kinase (ERK)1/2, p38/mitogen-acti-
vated protein kinase (MAPK), and NF-κB signaling pathways to
suppress production of cytokines and chemokines induced in the
THP-1 cell line stimulated with LPS.2. Materials and methods
2.1. Drugs and chemicals
Minocycline, doxycycline, U0126 and BAY11-7082 were pur-
chased from Sigma Chemical Company (St. Louis, MO, USA).SB203580 was purchased from Wako Industrial Company (Osaka,
Japan). Tigecycline was a gift from Pﬁzer Inc. (New York, NY, USA).
LPS from Pseudomonas aeruginosa Stereotype 10 (Sigma Chemical
Company) was used as a bacterial component that induces cyto-
kine and chemokine production. Tetracyclines were dissolved in
nanopure water and stored at 20 °C. LPS was dissolved in na-
nopure water and stored at 80 °C. Primary antibodies included
rabbit polyclonal anti-IκBα and phospho-IκBα, rabbit polyclonal
anti-IKKα and phospho-IKKα, rabbit polyclonal anti-IKKβ and
phospho-IKKβ, rabbit polyclonal anti-NF-κB and phospho-NF-κB,
rabbit polyclonal anti-phospho-ERK1/2, rabbit polyclonal anti-
phospho-p38 (all from Cell Signaling Technology, Beverly, MA,
USA), and rabbit polyclonal anti-actin antibody (Sigma Chemical
Company).
2.2. Cell culture and LPS stimulation
The THP-1 human monocytic leukemia cell line was purchased
from RIKEN Cell Bank (Wako, Japan). The cells were cultured in
RPMI-1640 medium with 10% FBS at 37 °C in humidiﬁed air with
5% CO2. THP-1 (5105/ml) cells added with LPS were incubated
for the indicated time in the presence of different antibiotics. Su-
pernatants were collected to measure cytokine and chemokine
production. Cell pellets were used for Western blotting analysis.
After treatment with LPS (10 μg/ml) without tetracyclines, with
minocycline (50 μg/ml), with tigecycline (50 μg/ml), or with dox-
ycycline (50 μg/ml), samples were collected 30, 60, 120 or 240 min
after treatment.
2.3. Cytokine and chemokine measurements
To measure cytokines and chemokines, we used the Multi Plex
Bead Immunoassay (Bio-Plex Suspension Array System, BIO-RAD
Laboratories, Inc., Hercules, CA, USA) as previously described [7].
We measured 12 cytokines or chemokines including TNF-α, TNF-β,
interferon (IFN)-γ, IL-1α, IL-1β, IL-8, IL-6, IL-12, IL-17, macrophage
inﬂammatory protein (MIP)-1α, MIP-1β, and vascular endothelial
growth factor (VEGF). The TNF-α and IL-8 enzyme-linked im-
munosorbent assay (ELISA) kits were purchased from Invitrogen
Corporation (Camerio, CA, USA). ELISA was conducted to conﬁrm
the TNF-α and IL-8 production after treatment with different
signal pathway inhibitors such as SB203580, U0126 and BAY11-
7082 in LPS-stimulated THP-1 cells. The experiments were per-
formed at least three times and the optical density of the samples
was measured at 450 nm using an automated ELISA reader
(SPECTRA max M5; Tokyo, Japan).
The values of the measured cytokines and chemokines were
shown (Fig. 1). Otherwise we calculated the ratio of the value at
each point (30 min, 60 min, 120 min, 240 min) to the control value.
We used the control value measured in LPS stimulated THP-1 cells
without tetracyclines. The values measured after administration of
tetracyclines were divided by the control value (Fig. 2).
2.4. Western blotting analysis
To elucidate modulation of signaling pathways, the protein le-
vels of phospho-ERK1/2 (Thr185/Tyr187), phospho-p38 (Thr180/
Tyr182), nuclear factor-κB alpha (IκBα) (Ser32), phospho-IκBα,
NF-κB, phospho-NF-κB, IKKα, phospho-IKKα, IKKβ, and phospho-
IKKβ were determined with Western blotting. Protein lysates were
electrophoretically separated on sodium dodecyl sulfate-poly-
acrylamide gels and transferred to polyvinylidene diﬂuoride
membranes. The membranes were probed with primary anti-
bodies followed by secondary antibodies. 5 μl antibodies were
diluted to 5 ml Phosphate Bufferd Salts with Tween. The ratio of
dilution was 1:1000. The signal was visualized and quantiﬁed
Fig. 1. (A) Time-dependent changes in cytokine and chemokine production in LPS-stimulated THP-1 cells. After LPS (10 μg/ml) treatment for 15, 30, 60, or 120 min without
any agents and with minocycline (50 μg/ml), tigecycline (50 μg/ml), or doxycycline (50 μg/ml), cytokines and chemokines were measured using Multi Plex according to the
manufacturer’s protocols. * po0.05 compared with LPS only at 60 min. ** po0.05 compared with LPS only at 120 min. Mino: minocycline, Tige: tigecycline, Doxy: dox-
ycycline. (B) The rate of cytokine and chemokine production in the THP-1 cell line compared to the production of cytokines and chemokines by LPS stimulation without
tetracyclines. After LPS treatment (10 μg/ml) for 30, 60, 120 or 240 min without any agents and with minocycline (50 μg/ml), tigecycline (50 μg/ml), or doxycycline (50 mg/
ml), cytokines and chemokines were measured with Multi Plex.
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Fig. 2. Effects of minocycline, doxycycline, and tigecycline on the modulation of NF-κB, phospho-NF-κB, IKKα/β, phospho-IKKα/β, IκBα, and phospho-IκBα in LPS-stimulated
THP-1 cells. THP-1 cells were incubated without or with 10 μg/ml LPS, or with LPS plus minocycline (50 μg/ml), doxycycline (50 μg/ml), or tigecycline (50 μg/ml) for 30, 60, or
120 min. NF-κB, phospho-NF-κB, IKKα/β, phospho-IKKα/β, IκBα, and phospho-IκBα were assessed with Western blotting.
J. Sun et al. / Biochemistry and Biophysics Reports 4 (2015) 397–404400using Image Quant LAS4000 mini apparatus (GE Healthcare, Up-
psala, Sweden) and Supersignal West Pico Chemiluminescent
Substrate (enhanced chemiluminescence) (Thermo Scientiﬁc
Company, Barrington, IL, USA).
2.5. Statistical analysis
All graphs were generated with GraphPad, Prism software
(GraphPad Software, Inc., San Diego, CA, USA). Data were pre-
sented as means7standard deviations (SD) and p values were
calculated using unpaired Student’s t-test with two-tailed analysis.
All statistical analyses were performed using Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA). A value of po0.05
was considered signiﬁcant.3. Results
3.1. Tetracycline modiﬁcation of LPS-induced cytokine and chemo-
kine production in THP-1 cells
Using the Multi Plex kit, we conﬁrmed that LPS induced cyto-
kine and chemokine production in THP-1 cell lines. TNF-β, IFN-γ,
IL-1α, IL-1β, IL-6, IL-12, IL-17, and VEGF were not signiﬁcantly
increased following LPS treatment. After treatment with LPS, cy-
tokines (TNF-α, IL-8) and chemokines (MIP-1α, MIP-1β) increased
rapidly beginning at 60 to 120 min and then reached stable levels.
Tetracyclines downregulated the release of cytokines and chemo-
kines. Minocycline inhibited TNF-α to 16.0% and 10.7% at 60 and
120 min, respectively. Tigecycline inhibited TNF-α to 14.0% and
66.6%, and doxycycline inhibited to 7.6% and 7.8%, respectively
(Fig. 1A), compared to control levels.At 60 and 120 min, minocycline inhibited IL-8 to 43.6% and 30.1%,
tigecycline inhibited the cytokine to 32.2% and 97.1%, and doxycycline
inhibited IL-8 to 25.9% and 10.3%, respectively, compared to control
levels. For MIP-1α at 60 and 120 min, minocycline induced 87.4% and
22.8% of control levels, tigecycline induced 165.0% and 32.6% of
control levels, and doxycycline induced 132.9% and 15.6% of control
levels, respectively. For MIP-1β at 60 and 120 min, minocycline in-
duced 58.2% and 20.6% of control levels, tigecycline induced 3.8% and
10.9% of control levels, and doxycycline induced 0% and 2.7% of
control levels, respectively (Fig. 1B). It was true that the ratios at
30 minwere rather too high and that were caused the data at 30 min
were unstable and within rather small range, the calculated values
might possibly give the misunderstanding. The production of cyto-
kines and chemokines increased gradually and reached the stable
level at 4–12 h after LPS stimulation [7]. Thereby the signiﬁcance of
the value at 30 min has not been clariﬁed previously. The ratio
showed the high values seemingly.
After treatment with LPS followed by tetracyclines, the pro-
duction of TNF-α and IL-8 was downregulated. Tigecycline in-
hibited production of both TNF-α and IL-8 at 60 min. Levels were
restored to control levels at 120 min. Minocycline and doxycycline
suppressed the production of TNF-α and IL-8 at 120 and 240 min.
For the production of MIP-1α and MIP-1β, signiﬁcant suppression
by minocycline and doxycycline was observed. Tigecycline did not
signiﬁcantly inhibit MIP-1β at 240 min. Thus, tetracyclines
downregulated cytokines and chemokines production in LPS-sti-
mulated THP-1 cells.
3.2. Effect of tetracyclines on the NF-κB signaling pathway in LPS-
stimulated THP-1 cells
To conﬁrm the effect of tetracyclines on the NF-κB signaling
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phospho-IKKα/β, IKKα/β, phospho-IκBα, and IκBα were assessed
with Western blotting. Phospho-NF-κB was signiﬁcantly increased
by LPS stimulation of THP-1 cells, suppressed by minocycline and
tigecycline at 30 min, and not suppressed after 120 min compared
with LPS alone. Doxycycline suppressed phosphorylation at 60 and
120 min. As regards, phosphorylation of IKKα/β, a similar result
was shown to phosphorylation of NF-κB in LPS-stimulated THP-1
cells. Minocyclin suppressed phospho-IKKα/β at 60 min and dox-
ycycline at 60 and 120 min compared with LPS alone. Phosphor-
ylation of IκBα was upregulated by LPS and downregulated by
tigecycline at 60 min. However, minocycline and doxycycline did
not signiﬁcantly suppress phospho-IκBα. Although the three tet-
racyclines showed some differences in time dependent course,
tetracyclines modulated phosphorylation of the IKKα/β, IκBα, and
NF-κB pathways, resulting in inhibition of cytokine and chemo-
kine production (Fig. 2).
3.3. Effect of tetracyclines on the p38 and ERK/MAPK pathways in
LPS-stimulated THP-1 cells
To investigate whether the MAPK signaling pathway was in-
volved in tetracycline modulation of LPS-induced cytokine and
chemokine release in THP-1 cells, phospho-ERK1/2 and phospho-
p38 were measured in the presence or absence of tetracyclines
after 30 and 60 min incubation periods. p38 phosphorylation was
signiﬁcantly activated by LPS stimulation in THP-1 cells. Among
the three tetracyclines, minocycline and doxycycline signiﬁcantly
suppressed p38 phosphorylation, but tigecycline did not, com-
pared with LPS alone. For the ERK/MAPK pathway, signal activa-
tion was induced by LPS stimulation of THP-1 cells after 60 min.
Compared with LPS only, minocycline induced an increase in
phospho-ERK1/2 activation at 30 min and the activation was de-
creased at 60 min after treatment. However, phosphorylation was
greater following treatment with the other two tetracyclines (ti-
gecycline and doxycycline) compared with minocycline 60 minFig. 3. Effects of tetracyclines (minocycline, doxycycline, and tigecycline) on the activati
were incubated without or with 10 μg/ml LPS, or with LPS plus minocycline (50 μg/ml), d
phospho-ERK1/2 were assessed with Western blotting.after treatment (Fig. 3).
3.4. Tetracyclines suppressed LPS-induced cytokines via both MAPK
and NF-κB pathways in THP-1 cells
To further conﬁrm the effect of different signal pathway on
cytokines production, after pre-incubation with U0126 (ERK/MAPK
inhibitor), SB203580 (p38/MAPK inhibitor) and BAY11-7082 (NF-
κB inhibitor), we detected the cytokines of TNF-α and IL-8 pro-
duction in LPS-stimulated THP-1 cells in present or absent of tet-
racyclines. As shown in Fig. 4, SB203580 and U0126 signiﬁcantly
suppressed the production of TNF-α and IL-8 in LPS-stimulated
THP-1 cells. And these inhibitory effects were emphasized by
treatment with tetracyclines. It suggested that both ERK/MAPK
and p38/MAPK pathways were involved in tetracyclines mod-
iﬁcation the production of LPS-induced cytokines in THP-1 cells. In
addition, the NF-κB inhibitor, BAY11-7082, almost completely
suppressed the LPS-induced TNF-α and IL-8 production in THP-1
cell. It suggested that NF-κB signaling pathway might be the
dominant pathway on tetracyclines modiﬁcation the production of
LPS-induced cytokines in THP-1 cells (Fig. 4).4. Discussion
Inﬂammation is a defensive response to numerous stimuli such
as injury, radiation, and pathogens, and occurs through various
inﬂammatory mediators such as cytokines and chemokines, which
coordinate host defense and repair [7]. Appropriate cytokine and
chemokine production is essential for the host and may involve
various immune-mediated processes, leading to protection of host
organs against pathogen invasion. However, uncontrolled in-
ﬂammatory responses can harm the host. Muroya et al. [15] re-
vealed that inﬂammatory cytokines exert cytotoxicity in the hu-
man alveolar epithelial cell line A549. A mixture of IL-1β, TNF-α,
and IFN-γ, designated as a “cytomix”, shows augmentedon of phospho-ERK1/2 and phospho-p38 in LPS-stimulated THP-1 cells. THP-1 cells
oxycycline (50 μg/ml), or tigecycline (50 μg/ml) for 30 or 60 min. Phospho-p38 and
Fig. 4. SB203580, U0126 and BAY11-7082 suppressed TNF-α and IL-8 production in LPS-stimulated THP-1 cells on treatment with or without tetracyclines. THP-1 cells were
pre-incubated by SB203580 (10 μM), U0126 (5 μM) and BAY11-7082 (5 μM) for 30 min, followed treatment without or with LPS (10 μg/ml), or with LPS (10 μg/ml) plus
minocycline (50 μg/ml), doxycycline (50 μg/ml), or tigecycline (50 μg/ml) for 60 min. TNF-α were measured with ELISA. *po0.05, **po0.01, ***po0.001 compared to the
measurement without the inhibitor in the same group. Abbreviation; SB: SB203580, U: U0126, BAY: BAY11-7082.
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Therefore, over-expression of cytokines and chemokines may lead
to secondary damage and a systemic disorder in the organism
such as septic shock. LPS, the major component of the outer
membrane of gram-negative bacteria, is the main factor re-
sponsible for microglial activation [16]. Cytokine and chemokine
production induced by LPS both in vivo and in vitro has been re-
ported in previous studies [17,18]. In the present study, cytokines
(TNF-α, IL-8) and chemokines (MIP-1α, MIP-1β) increased rapidly
beginning at 60 min after LPS (10 μg/ml) stimulation of THP-1
cells. Therefore, we used this concentration of LPS as the experi-
mental model for further evaluating the immunomodulatory ef-
fects of tetracyclines. Minocycline and doxycycline showed the
effect on the suppression of the production more than 4 h after
LPS administration, but as for tigecycline, the production re-
covered at 2–4 h.
Tetracyclines show various activities besides of antimicrobial
activity [8,14,19,20]. These non-antibiotic, anti-inﬂammatory
properties suggest that tetracyclines may provide additional clin-
ical beneﬁts for the treatment of some non-bacterial diseases, such
as allergic asthma [21], rickettsial infections [22,23], rheumatoid
arthritis [24,25], neurodegenerative diseases [26,27] and malig-
nant tumors [28,29]. Due to the pleiotropic effects of tetracyclines,
the immunostimulatory effect on monocytes may contradict its
useful effects for the treatment of several kinds of chronic in-
ﬂammation. However, the precise mechanism of modulation of the
production of cytokines and chemokines by tetracyclines is still
unknown. In addition, as far as we know, no report has shown a
comparison among three tetracyclines. Accordingly, we in-
vestigated the different mechanisms of the immunomodulatoryeffects on cytokines and chemokines by three different tetra-
cyclines in THP-1 cells.
NF-κB is a key regulator of the transcription of many in-
ﬂammatory cytokines [30]. NF-κB translocation into the nucleus is
preceded by the phosphorylation of IκBα, a protein that normally
sequesters the NF-κB complex in the cytosol in an inactive form.
Following inﬂammatory stimuli, phosphorylation and degradation
of IκBα allow the NF-κB heterodimer to rapidly move into the
nucleus [30,31]. MAPKs are important factors of inﬂammatory and
stress-induced signal pathways which regulated cell survival and
death. The ERK signal pathway is induced primarily by mitogenic
stimuli and growth factors; otherwise the p38 signal pathway is
induced primarily by various stresses including inﬂammation [32].
Previous reports also showed that minocycline decreases the
production of multiple cytokines and chemokines by inhibiting
LPS-induced IKKα/β phosphorylation in THP-1 cells [7]. In this
study, we found that minocycline induced an increase in phosoho-
ERK1/2 activation and suppressed phospho-NF-κB at 30 min.
Clinically speaking, most patients with tsutsugamushi disease in
Japan, a rickettsial infection disease, show antipyretic and recover
quickly when treated with minocycline [33]. This clinical effect
may be partly due to rapid modiﬁcation of signaling pathways by
minocycline followed by suppression of cytokine and chemokine
production induced by pathogens. In addition, minocycline not
only modulates the NF-κB pathway but also suppresses p38
phosphorylation and activates ERK1/2 phosphorylation. Thus,
more than one signaling pathway is involved in minocycline
downregulation of the expression of LPS-induced cytokines and
chemokines in human THP-1 cells. Doxycycline was recently
shown to upregulate the expression of the cytokines IL-6 and
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and NF-κB pathways in mouse thymic epithelial cells [33]. Dox-
ycycline prevents LPS-induced endothelial barrier dysfunction by
inhibiting the activation of the p38/MAPK pathway in human
umbilical vein endothelial cells [34]. Here, we evaluated that
doxycycline activated phospho-ERK1/2 and suppressed phospho-
p38 and phospho-NF-κB 60 min after treatment. Therefore, our
results demonstrated that doxycycline can modify both MAPK
(p38 and ERK) and NF-κB pathways in THP-1 cells. As shown
above, tigecycline suppresses the expression of LPS-induced TNF-α
and IL-1β in rat PC12 cells via NF-κB signaling pathways [13].
However, in present study, tigecycline also downregulated the
expression of LPS-induced cytokines and chemokines not only by
suppressing phosphorylation of NF-κB, but also by suppressing
phosphorylation of p38 and activation of the ERK1/2 pathway.
Sheth et al. reported that p38 inhibition by SB203580 enhances
ERK activity during endotoxemia. They suggested that interaction
between the ERK and p38/MAPK pathways induced the apoptotic
potential of polymorphonuclear neutrophils in inﬂammatory
states [35]. In our study, SB203580 (p38 inhibitor) and U0126
(ERK1/2 inhibitor) signiﬁcantly suppressed the production of TNF-
α and IL-8 in LPS-stimulated THP-1 cells. And cytokines were
further suppressed by treatment of tetracyclines, indicating that
the MAPKs are partially associated with the cytokine production.
In addition, BAY11-7082 (NF-κB inhibitor) almost completely
suppressed LPS-induced cytokine production. Furthermore, de-
spite the phosphorylation levels of upstream signaling molecules,
our data showed that p-NF-κB levels were ﬁnally suppressed by
the three independent tertacyclines at 60 min after LPS stimula-
tion. These ﬁndings suggested that NF-κB pathway would be the
most striking target on tetracyclines modiﬁcation due to the LPS-
induced cytokine productions in THP-1 cells.
In conclusion, the production of LPS-induced cytokines (TNF-α,
IL-8) and chemokines (MIP-1α, MIP-1β) was suppressed by three
tetracycline derivatives, minocycline, tigecycline, and doxycycline,
in THP-1 cells. However, the mechanisms of action of the three
tetracyclines were different. More than one cell signaling pathway
may be involved in downregulation of the expression of LPS-in-
duced cytokines and chemokines by tetracyclines in THP-1 cells.
Among the three signaling pathways, NF-κB pathway might be the
dominant pathway. The effects of tetracyclines on cytokine and
chemokine production may be expected for the treatment of the
cytokine storm in bacterial infectious diseases. It is necessary to
consider about the difference between tigecycline and others in
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